TWIST BIOSCIENCE CORP (TWST) Fundamental Analysis & Valuation
NASDAQ:TWST • US90184D1000
Current stock price
49.4 USD
+1.91 (+4.02%)
Last:
This TWST fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. TWST Profitability Analysis
1.1 Basic Checks
- TWST had negative earnings in the past year.
- In the past year TWST has reported a negative cash flow from operations.
- TWST had negative earnings in each of the past 5 years.
- TWST had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
- Looking at the Return On Assets, with a value of -12.00%, TWST belongs to the top of the industry, outperforming 81.50% of the companies in the same industry.
- TWST has a better Return On Equity (-16.79%) than 83.43% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -12% | ||
| ROE | -16.79% | ||
| ROIC | N/A |
ROA(3y)-24.14%
ROA(5y)-23.35%
ROE(3y)-31.13%
ROE(5y)-29.44%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- With a decent Gross Margin value of 51.62%, TWST is doing good in the industry, outperforming 75.72% of the companies in the same industry.
- In the last couple of years the Gross Margin of TWST has grown nicely.
- TWST does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 51.62% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y7.04%
GM growth 5Y9.75%
2. TWST Health Analysis
2.1 Basic Checks
- TWST does not have a ROIC to compare to the WACC, probably because it is not profitable.
- Compared to 1 year ago, TWST has more shares outstanding
- The number of shares outstanding for TWST has been increased compared to 5 years ago.
- TWST has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
- TWST has an Altman-Z score of 6.98. This indicates that TWST is financially healthy and has little risk of bankruptcy at the moment.
- TWST has a better Altman-Z score (6.98) than 78.03% of its industry peers.
- There is no outstanding debt for TWST. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 6.98 |
ROIC/WACCN/A
WACC9.28%
2.3 Liquidity
- A Current Ratio of 3.78 indicates that TWST has no problem at all paying its short term obligations.
- TWST's Current ratio of 3.78 is in line compared to the rest of the industry. TWST outperforms 45.09% of its industry peers.
- TWST has a Quick Ratio of 3.37. This indicates that TWST is financially healthy and has no problem in meeting its short term obligations.
- TWST has a Quick ratio (3.37) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.78 | ||
| Quick Ratio | 3.37 |
3. TWST Growth Analysis
3.1 Past
- The Earnings Per Share has grown by an impressive 38.46% over the past year.
- The Revenue has grown by 18.59% in the past year. This is quite good.
- The Revenue has been growing by 33.11% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)38.46%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%5.66%
Revenue 1Y (TTM)18.59%
Revenue growth 3Y22.75%
Revenue growth 5Y33.11%
Sales Q2Q%16.89%
3.2 Future
- Based on estimates for the next years, TWST will show a quite strong growth in Earnings Per Share. The EPS will grow by 17.58% on average per year.
- TWST is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 15.32% yearly.
EPS Next Y12.86%
EPS Next 2Y17%
EPS Next 3Y17.58%
EPS Next 5YN/A
Revenue Next Year17.17%
Revenue Next 2Y16.12%
Revenue Next 3Y15.91%
Revenue Next 5Y15.32%
3.3 Evolution
- Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. TWST Valuation Analysis
4.1 Price/Earnings Ratio
- TWST reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TWST. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- TWST's earnings are expected to grow with 17.58% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y17%
EPS Next 3Y17.58%
5. TWST Dividend Analysis
5.1 Amount
- No dividends for TWST!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
TWST Fundamentals: All Metrics, Ratios and Statistics
NASDAQ:TWST (3/25/2026, 3:27:10 PM)
49.4
+1.91 (+4.02%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-02 2026-02-02/bmo
Earnings (Next)05-04 2026-05-04
Inst Owners121.85%
Inst Owner Change1.96%
Ins Owners1.48%
Ins Owner Change5.79%
Market Cap3.03B
Revenue(TTM)391.56M
Net Income(TTM)-76.58M
Analysts84.71
Price Target51.61 (4.47%)
Short Float %21.09%
Short Ratio9.46
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-8.39%
Min EPS beat(2)-14%
Max EPS beat(2)-2.79%
EPS beat(4)1
Avg EPS beat(4)-2.91%
Min EPS beat(4)-14%
Max EPS beat(4)17.53%
EPS beat(8)4
Avg EPS beat(8)-7.26%
EPS beat(12)8
Avg EPS beat(12)0.24%
EPS beat(16)12
Avg EPS beat(16)6.24%
Revenue beat(2)1
Avg Revenue beat(2)0.3%
Min Revenue beat(2)-0.26%
Max Revenue beat(2)0.85%
Revenue beat(4)1
Avg Revenue beat(4)-0.51%
Min Revenue beat(4)-1.51%
Max Revenue beat(4)0.85%
Revenue beat(8)5
Avg Revenue beat(8)0.83%
Revenue beat(12)9
Avg Revenue beat(12)1.76%
Revenue beat(16)11
Avg Revenue beat(16)1.82%
PT rev (1m)6.75%
PT rev (3m)31.37%
EPS NQ rev (1m)-0.23%
EPS NQ rev (3m)-10.9%
EPS NY rev (1m)-7.48%
EPS NY rev (3m)-19.53%
Revenue NQ rev (1m)-0.02%
Revenue NQ rev (3m)2.07%
Revenue NY rev (1m)1.09%
Revenue NY rev (3m)3.24%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 7.74 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 6.64 | ||
| P/tB | 8.4 | ||
| EV/EBITDA | N/A |
EPS(TTM)-2.08
EYN/A
EPS(NY)-1.33
Fwd EYN/A
FCF(TTM)-1.41
FCFYN/A
OCF(TTM)-0.83
OCFYN/A
SpS6.39
BVpS7.44
TBVpS5.88
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -12% | ||
| ROE | -16.79% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 51.62% | ||
| FCFM | N/A |
ROA(3y)-24.14%
ROA(5y)-23.35%
ROE(3y)-31.13%
ROE(5y)-29.44%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y7.04%
GM growth 5Y9.75%
F-Score5
Asset Turnover0.61
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 144.77% | ||
| Cap/Sales | 9.12% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.78 | ||
| Quick Ratio | 3.37 | ||
| Altman-Z | 6.98 |
F-Score5
WACC9.28%
ROIC/WACCN/A
Cap/Depr(3y)74.54%
Cap/Depr(5y)223.62%
Cap/Sales(3y)6.8%
Cap/Sales(5y)18.18%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)38.46%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%5.66%
EPS Next Y12.86%
EPS Next 2Y17%
EPS Next 3Y17.58%
EPS Next 5YN/A
Revenue 1Y (TTM)18.59%
Revenue growth 3Y22.75%
Revenue growth 5Y33.11%
Sales Q2Q%16.89%
Revenue Next Year17.17%
Revenue Next 2Y16.12%
Revenue Next 3Y15.91%
Revenue Next 5Y15.32%
EBIT growth 1Y17.76%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year70.31%
EBIT Next 3Y29.55%
EBIT Next 5Y23.24%
FCF growth 1Y32.69%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y54.2%
OCF growth 3YN/A
OCF growth 5YN/A
TWIST BIOSCIENCE CORP / TWST Fundamental Analysis FAQ
Can you provide the ChartMill fundamental rating for TWIST BIOSCIENCE CORP?
ChartMill assigns a fundamental rating of 4 / 10 to TWST.
What is the valuation status for TWST stock?
ChartMill assigns a valuation rating of 0 / 10 to TWIST BIOSCIENCE CORP (TWST). This can be considered as Overvalued.
How profitable is TWIST BIOSCIENCE CORP (TWST) stock?
TWIST BIOSCIENCE CORP (TWST) has a profitability rating of 3 / 10.
Can you provide the expected EPS growth for TWST stock?
The Earnings per Share (EPS) of TWIST BIOSCIENCE CORP (TWST) is expected to grow by 12.86% in the next year.